Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Does CAR-T Therapy Overcome TP53-Driven Resistance in Lymphoma? A Systematic Review of Clinical Outcomes

CT - 126

Does CAR-T Therapy Overcome TP53-Driven Resistance in Lymphoma? A Systematic Review of Clinical Outcomes

Mostafa F Mohammed Saleh

Poster Presenter: Mostafa F Mohammed Saleh

Thumbnail for Association Between Statin Use and Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis

MM - 127

Association Between Statin Use and Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis

Caryn Louise Gutierrez

Poster Presenter: Caryn Louise Gutierrez

Thumbnail for Efficacy and Safety of Ropeginterferon in Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis

Previous 1...8 9 10 11 12 13 14...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

MPN - 129

Efficacy and Safety of Ropeginterferon in Myeloproliferative Neoplasms: A Systematic Review and Meta-Analysis

Mahmood Aldapt

Poster Presenter: Mahmood Aldapt

Thumbnail for Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

MM - 130

Does Minimal Residual Disease Negativity Overcome High-Risk Cytogenetics After Autologous Stem Cell Transplantation in Multiple Myeloma?

Rithika Manjunatha Reddy

Poster Presenter: Rithika Manjunatha Reddy

Thumbnail for Immune Effector Cell (IEC)-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients With Hematologic Malignancies: A Systematic Review and Meta-Analysis

CT - 131

Immune Effector Cell (IEC)-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients With Hematologic Malignancies: A Systematic Review and Meta-Analysis

Motaz Almahmood

Poster Presenter: Motaz Almahmood

Thumbnail for Efficacy and Toxicity of FLAG-IDA-Venetoclax Compared With Other Induction Regimens in Newly Diagnosed and Relapsed AML: A Real-World Single-Center Study

AML - 132

Efficacy and Toxicity of FLAG-IDA-Venetoclax Compared With Other Induction Regimens in Newly Diagnosed and Relapsed AML: A Real-World Single-Center Study

Rita Ahmad

Poster Presenter: Rita Ahmad

$Thumbnail for Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis$

MM - 134

Durable Clinical Benefit of B-Cell Maturation Antigen (BCMA)-Directed Therapy With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) in Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-8 Long-Term Responder (LTR) Analysis

Meletios A Dimopoulos

Poster Presenter: Meletios A Dimopoulos

Thumbnail for Comparative Effectiveness of Standard 3+7 Versus FLAG/FLAG-IDA Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Propensity Score-Matched Cohort Study Using the TriNetX Global Network

AML - 138

Comparative Effectiveness of Standard 3+7 Versus FLAG/FLAG-IDA Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Propensity Score-Matched Cohort Study Using the TriNetX Global Network

Rita Ahmad

Poster Presenter: Rita Ahmad

$Thumbnail for Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma$

IBCL - 141

Golcadomide, a Potential First-in-Class, Oral Celmod ± Rituximab in the Phase 1/2 CC-99282-NHL-001 Study: Long-Term Follow-Up Results of Patients With Relapsed/Refractory Follicular Lymphoma

Javier Munoz

Poster Presenter: Javier Munoz

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors